Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

NCT05050474 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID19

Interventions

BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine

Sponsor

Livzon Pharmaceutical Group Inc.

Collaborators

[object Object]
[object Object]